---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-23-059242"
form_type: "8-K"
ticker: null
cik: "0000316253"
company_name: "ENZO BIOCHEM INC"
filed_at: "2023-07-24T23:59:59+00:00"
generated_at: "2026-06-13T04:34:28.200949+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Enzo Biochem closes clinical lab sale to Labcorp for $113.25M cash; exits lab business

## Summary
- Asset sale of Enzo Clinical Labs to Labcorp closed on July 24, 2023 for aggregate cash consideration of $113.25 million.
- Enzo will cease all clinical laboratory operations and focus on its life sciences business.
- Transaction was previously announced on March 16, 2023 and amended on July 3, 2023.
- Jefferies and McDermott Will & Emery advised Enzo; Evercore and Hogan Lovells advised Labcorp.

## SEC filing metadata
- accession: 0001213900-23-059242
- form_type: 8-K
- cik: 0000316253
- company_name: ENZO BIOCHEM INC
- filed_at: 2023-07-24T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/316253/000121390023059242/0001213900-23-059242-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/316253/000121390023059242/ea182199-8k_enzobiochem.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-23-059242
- JSON: https://secwatch.observer/filing/0001213900-23-059242.json
- Plain text: https://secwatch.observer/filing/0001213900-23-059242.txt

## Key facts
- M&A Transactions
  ENZO BIOCHEM INC completed a disposition involving Laboratory Corporation of America Holdings for $113.25 million in cash (closed 2023-07-24).
  - Action: disposition
  - Counterparty: Laboratory Corporation of America Holdings
  - Consideration: $113.25 million in cash
  - Closing: 2023-07-24
  source text: On July 24, 2023 (the “Closing Date”), pursuant to the terms of the Asset Purchase Agreement, as amended (the “Purchase Agreement”), by and among Enzo Biochem, Inc., a New York corporation (the “Company”), Enzo Clinical Labs, Inc., a New York corporation, and Laboratory Corporation of America Holdings, a Delaware corporation, the Company closed the sale of certain assets and assignment of certain liabilities of the Company’s clinical laboratory business (the “Asset Sale”) for $113.25 million in cash (the “Purchase Price”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/316253/000121390023059242/0001213900-23-059242-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.